InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Inmune Bio, Inc.

INMB Clue Score30
United States Fiscal year ends December CIK 0001711754
$1.89 +3.28% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.89 −89.41% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 4 Feb 2019. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2017Revenue0.0Operating income−1.0Net income−0.8Fiscal year 2018Revenue0.0Operating income−12.4Net income−12.4Fiscal year 2019Operating income−7.8Net income−7.7Fiscal year 2020Revenue0.0Operating income−12.2Net income−12.1Fiscal year 2021Revenue0.2 +1,545.5%Operating income−29.2Net income−30.3EPS, diluted−1.88Fiscal year 2022Revenue0.4 +106.6%Operating income−26.0Net income−27.3EPS, diluted−1.52Fiscal year 2023Revenue0.2 −58.6%Operating income−29.7Net income−30.0EPS, diluted−1.67Fiscal year 2024Revenue0.0 −91.0%Operating income−42.6Net income−42.1EPS, diluted−2.11Fiscal year 2025Revenue0.1 +257.1%Operating income−47.4Net income−45.9EPS, diluted−1.86
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 0.0 0.0 n/a 0.0 0.2 0.4 0.2 0.0 0.1
Growth +1,545.5% +106.6% −58.6% −91.0% +257.1%
Operating income −1.0 −12.4 −7.8 −12.2 −29.2 −26.0 −29.7 −42.6 −47.4
Net income −0.8 −12.4 −7.7 −12.1 −30.3 −27.3 −30.0 −42.1 −45.9
Growth
EPS, diluted n/a n/a n/a n/a −1.88 −1.52 −1.67 −2.11 −1.86
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Operating margin−111,163.6%Net margin−109,990.9%Fiscal year 2021Operating margin−16,106.6%Net margin−16,762.4%Fiscal year 2022Operating margin−6,938.8%Net margin−7,299.2%Fiscal year 2023Operating margin−19,187.7%Net margin−19,360.0%Fiscal year 2024Operating margin−304,535.7%Net margin−300,585.7%Fiscal year 2025Operating margin−94,766.0%Net margin−91,866.0%Free cash flow margin−47,248.0%
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a −111,163.6% −16,106.6% −6,938.8% −19,187.7% −304,535.7% −94,766.0%
Net margin n/a n/a n/a −109,990.9% −16,762.4% −7,299.2% −19,360.0% −300,585.7% −91,866.0%
Free cash flow margin n/a n/a n/a n/a n/a n/a n/a n/a −47,248.0%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−0.8Fiscal year 2018Operating cash flow−2.1Fiscal year 2019Operating cash flow−5.4Fiscal year 2020Operating cash flow−8.9Fiscal year 2021Operating cash flow−28.5Fiscal year 2022Operating cash flow−22.7Fiscal year 2023Operating cash flow−12.0Fiscal year 2024Operating cash flow−33.4Fiscal year 2025Operating cash flow−22.6Capital expenditure−1.0Free cash flow−23.6
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −0.8 −2.1 −5.4 −8.9 −28.5 −22.7 −12.0 −33.4 −22.6
Capital expenditure n/a n/a n/a n/a n/a n/a n/a n/a −1.0
Free cash flow n/a n/a n/a n/a n/a n/a n/a n/a −23.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2017Cash1.4Shareholders’ equity18.1Fiscal year 2018Cash0.2Shareholders’ equity16.5Fiscal year 2019Cash7.0Shareholders’ equity23.6Fiscal year 2020Cash22.0Shareholders’ equity38.8Fiscal year 2021Cash74.8Total debt15.0Net cash (debt)59.8Shareholders’ equity80.2Debt to equity0.19Fiscal year 2022Cash52.2Total debt14.7Net cash (debt)37.5Shareholders’ equity60.1Debt to equity0.24Fiscal year 2023Cash35.8Total debt9.9Net cash (debt)25.9Shareholders’ equity37.3Debt to equity0.27Fiscal year 2024Cash20.9Total debt15.0Net cash (debt)5.9Shareholders’ equity32.1Debt to equity0.47Fiscal year 2025Cash24.8Shareholders’ equity23.5
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 1.4 0.2 7.0 22.0 74.8 52.2 35.8 20.9 24.8
Total debt n/a n/a n/a n/a 15.0 14.7 9.9 15.0 n/a
Net cash (debt) n/a n/a n/a n/a 59.8 37.5 25.9 5.9 n/a
Shareholders’ equity 18.1 16.5 23.6 38.8 80.2 60.1 37.3 32.1 23.5
Debt to equity n/a n/a n/a n/a 0.19 0.24 0.27 0.47 n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.0 0.0 n/a 0.0 0.2 0.4 0.2 0.0 0.1
Growth +1,545.5% +106.6% −58.6% −91.0% +257.1%
0.4 3.4 3.3 5.9 20.5 17.1 20.3 33.2 20.7
0.5 9.1 6.0 6.3 8.8 9.3 9.6 9.5 10.3
−1.0 −12.4 −7.8 −12.2 −29.2 −26.0 −29.7 −42.6 −47.4
Growth
n/a n/a n/a n/a n/a n/a 30.0 42.1 45.9
0.0 0.0 n/a n/a n/a n/a n/a n/a n/a
−0.8 −12.4 −7.7 −12.1 −30.3 −27.3 −30.0 −42.1 −45.9
Growth
Per share
n/a n/a n/a n/a −1.88 −1.52 −1.67 −2.11 −1.86
n/a n/a n/a n/a −1.88 −1.52 −1.67 −2.11 −1.86
Growth
n/a n/a n/a n/a 16.1 17.9 18.0 19.9 24.8
n/a n/a n/a n/a 16.1 17.9 18.0 19.9 24.8
Growth +11.1% +0.3% +10.9% +24.1%

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 35.4% a year over five years.
  • Operating margin is up 16,397.6 points on five years ago, at -94,766.0%.
  • A net loss in 9 of 9 years on file.